JP2024522494A5 - - Google Patents
Info
- Publication number
- JP2024522494A5 JP2024522494A5 JP2023572751A JP2023572751A JP2024522494A5 JP 2024522494 A5 JP2024522494 A5 JP 2024522494A5 JP 2023572751 A JP2023572751 A JP 2023572751A JP 2023572751 A JP2023572751 A JP 2023572751A JP 2024522494 A5 JP2024522494 A5 JP 2024522494A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound according
- disorder
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051003A JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21177660.4 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21188639.5 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 | ||
| EP21215875.2 | 2021-12-20 | ||
| PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051003A Division JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522494A JP2024522494A (ja) | 2024-06-21 |
| JP2024522494A5 true JP2024522494A5 (https=) | 2025-04-03 |
| JP7705963B2 JP7705963B2 (ja) | 2025-07-10 |
Family
ID=82115763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572751A Active JP7705963B2 (ja) | 2021-06-04 | 2022-06-02 | トリアジン誘導体およびがんの処置におけるその使用 |
| JP2025051003A Pending JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051003A Pending JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (https=) |
| EP (1) | EP4347571B1 (https=) |
| JP (2) | JP7705963B2 (https=) |
| KR (1) | KR20240019083A (https=) |
| AR (1) | AR126053A1 (https=) |
| AU (1) | AU2022287224A1 (https=) |
| BR (1) | BR112023025318A2 (https=) |
| CA (1) | CA3216026A1 (https=) |
| CL (1) | CL2023003491A1 (https=) |
| CO (1) | CO2023016212A2 (https=) |
| CR (1) | CR20230566A (https=) |
| IL (1) | IL307201A (https=) |
| MX (1) | MX2023013998A (https=) |
| PE (1) | PE20240928A1 (https=) |
| TW (1) | TW202313577A (https=) |
| WO (1) | WO2022253936A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3218212A1 (en) * | 2021-04-28 | 2022-11-03 | Astellas Pharma Inc. | Substituted triazine compound |
| TW202313577A (zh) * | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| IL314025A (en) * | 2022-01-07 | 2024-08-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and uses thereof |
| EP4558499A1 (en) * | 2022-07-21 | 2025-05-28 | F. Hoffmann-La Roche AG | Nlrp3 inhibitors |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| AU2023371859A1 (en) * | 2022-11-04 | 2025-06-12 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| PE20251845A1 (es) * | 2022-12-07 | 2025-07-17 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibicion de nlrp3 |
| JP2026511027A (ja) * | 2023-03-20 | 2026-04-10 | インシリコ メディスン アイピー リミティド | Ｎｌｒｐ３インフラマソーム阻害剤及びその使用 |
| WO2024193699A1 (zh) * | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| TW202448448A (zh) * | 2023-04-19 | 2024-12-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| AU2024258000A1 (en) * | 2023-04-19 | 2025-08-14 | F. Hoffmann-La Roche Ag | Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| WO2025046419A1 (ko) * | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
| WO2026046981A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028440A1 (en) * | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| MX2020009957A (es) * | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compuestos para el tratamiento de enfermedad de hungtinton. |
| KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| EP4093509A1 (en) | 2020-01-22 | 2022-11-30 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as nlrp3 modulators |
| CN115279739B (zh) | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| WO2022135567A1 (zh) | 2020-12-25 | 2022-06-30 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
| EP4289823A4 (en) | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3218212A1 (en) | 2021-04-28 | 2022-11-03 | Astellas Pharma Inc. | Substituted triazine compound |
| TW202313577A (zh) * | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| CN115433163A (zh) | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| LT4363406T (lt) | 2021-07-02 | 2025-12-29 | Astrazeneca Ab | Nlrp3 inflamasomų inhibitoriai |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| IL314025A (en) | 2022-01-07 | 2024-08-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and uses thereof |
| CA3246681A1 (en) | 2022-03-25 | 2023-09-28 | Ventus Therapeutics U.S., Inc. | PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES |
| JPWO2024090469A1 (https=) | 2022-10-26 | 2024-05-02 | ||
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| AU2023371859A1 (en) | 2022-11-04 | 2025-06-12 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| TW202440107A (zh) | 2022-12-28 | 2024-10-16 | 瑞典商阿斯特捷利康公司 | Ｎｌｒｐ３炎症小體抑制劑 |
| WO2024169858A1 (zh) | 2023-02-17 | 2024-08-22 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 EP EP22731614.8A patent/EP4347571B1/en active Active
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024522494A5 (https=) | ||
| JP2024540445A5 (https=) | ||
| JP6505013B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| US20240374595A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| JP5600685B2 (ja) | ジペプトイドプロドラッグおよびそれらの使用 | |
| JP2020532506A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| TW201927766A (zh) | Hiv蛋白酶抑制劑 | |
| JP2024517917A5 (https=) | ||
| JP2023543059A5 (https=) | ||
| JP2007524683A5 (https=) | ||
| JP2017537158A5 (https=) | ||
| CN1794988B (zh) | 用于治疗血管渗透性过高疾病的组合物 | |
| JP2005515172A5 (https=) | ||
| JP2022008860A5 (https=) | ||
| IL196129A (en) | Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis | |
| JP2013544276A5 (https=) | ||
| JP2012512203A (ja) | アミノ酸エステルのプロドラッグおよびその使用 | |
| JP2019500387A5 (https=) | ||
| US10117864B2 (en) | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | |
| JP2024540525A5 (https=) | ||
| JP2024518556A5 (https=) | ||
| JP2016540811A5 (https=) | ||
| JP2008517923A5 (https=) | ||
| JP2008534453A (ja) | 再灌流傷害および再灌流障害の処置のための置換２−チオ−３，５−ジシアノ−４−フェニル−６−アミノピリジンの使用 |